Bengkel produktif Nexus Produktiviti Farmaseutikal (PPN) dengan kerjasama Kementerian Kesihatan Malaysia (KKM) ini berjaya mencapai beberapa hasil signifikan dalam memperkukuh daya saing sektor farmaseutikal negara. Sesi telah memberi pendedahan praktikal terhadap proses, tatacara dan dokumentasi perolehan kerajaan yang sering menjadi cabaran utama kepada pemain industri. Antara hasil utama bengkel ini: ✅ Peningkatan kefahaman peserta terhadap kehendak teknikal dan prosedur perolehan kerajaan, termasuk isu-isu yang sering menjadi punca kelewatan atau ketidakpatuhan; ✅ Penyelarasan persepsi antara sektor awam dan swasta, dengan perbincangan terbuka yang meneliti jurang kefahaman serta cadangan penambahbaikan proses perolehan; ✅ Komitmen industri dan pihak kerajaan untuk melaksanakan amalan perolehan yang lebih telus dan efisien, selaras dengan aspirasi meningkatkan daya tahan sistem kesihatan negara.

The productive discussion during the PPN Governing Committee Meeting 2/2025 was chaired by Champion Encik Ch’ng Kien Peng and attended by representatives from public agencies including MITI, MOH, MOSTI, NPRA, MPC and MIDA as well as industry leaders. The meeting focused on aligning high-impact initiatives to advance the pharmaceutical manufacturing sector. NGC members are committed to boosting the productivity of the pharmaceutical industry with the goal of establishing Malaysia as a leading pharmaceutical hub. The discussion focused on enhancing productivity by addressing talent mismatch, streamlining regulations and standards, and driving the sector toward high-tech innovation. The meeting was highly focused and outcome-driven, emphasizing collaborative strategies and actionable plans to accelerate industry growth and competitiveness.

Sesi produktif bersama National Pharmaceutical Regulatory Agency (NPRA) telah diadakan bagi memahami serta mengenal pasti peluang penambahbaikan dalam proses dan keperluan pendaftaran produk farmaseutikal. Penambahbaikan ini dilaksanakan melalui kajian menyeluruh yang memfokuskan kepada pematuhan peraturan, kelancaran aliran kerja, dan penyeragaman dokumen supaya proses pendaftaran menjadi lebih jelas, teratur, serta mudah dijadikan rujukan oleh pihak industri. Sebagai langkah susulan, PPN akan melaksanakan pemetaan proses dan tempoh semasa pendaftaran iaitu 210 hari bekerja bagi produk generik dan 240 hari bekerja bagi produk NCE/biologik bagi mengenal pasti kelewatan dalam proses dalaman NPRA. Sesi libat urus bersama pihak berkepentingan dan industri farmaseutikal juga akan diadakan bagi mengesahkan data serta berkongsi pengalaman permohonan dan cadangan penambahbaikan terhadap isu kelewatan tersebut. Di samping itu, analisa perbandingan proses dan prosedur di negara jiran seperti Thailand dan Singapura akan dilakukan. Hasil dapatan kajian akan dirumuskan dalam laporan yang mengandungi analisa, pengesyoran penambahbaikan berasaskan bukti, data, dan amalan terbaik.

A workshop was conducted to discuss the technical requirements set by the Fire and Rescue Department of Malaysia (BOMBA) for pharmaceutical plant approvals. The session brought together industry representatives and technical consultants to examine key issues and challenges affecting productivity in the pharmaceutical sector. This initiative was prompted by industry feedback highlighting significant delays in the development of pharmaceutical plants—often taking more than seven years—due to unclear and misunderstood technical requirements, particularly those related to BOMBA approvals. The discussions aimed to clarify BOMBA’s fire safety compliance procedures, identify recurring bottlenecks, and explore practical solutions to improve the overall efficiency of the approval process. Case studies were shared to provide real-world context and promote a better understanding of how technical requirements can be met without unnecessary delays. Industry participants were also facilitated and advised by experts on BOMBA requirements through the review and assessment of their construction plans. The workshop provided an important platform for sharing knowledge and offering technical guidance. It represented a positive move toward improving the pharmaceutical plant approval process while ensuring compliance with strict safety standards. Moving forward, the session will contribute to the development of practical guidelines aimed at harmonizing the approval process making it more efficient, structured, and aligned with industry needs.

Betamek R&D Centre is leading efforts to reinforce Malaysia’s commitment to energy efficiency through a structured and results-driven action plan. This initiative integrates both hardware and software enhancements, with a strong focus on measuring return on investment (ROI) and key performance indicators (KPIs) to ensure tangible outcomes. A major milestone in this effort is the deployment of locally manufactured digital power meters, demonstrating Betamek’s firm support for homegrown technology and innovation. The initiative is further strengthened by strategic partners such as Econos, Whatif, Advantech, and Solarvest EE each contributing niche expertise under the Overall Equipment Effectiveness (OEEE) framework. The Malaysia Productivity Corporation (MPC), serving as the government’s strategic partner, will facilitate industry-wide engagement, particularly among companies registered under the 14 Productivity Nexus. Through a series of briefings, events, and knowledge-sharing sessions, Betamek and its partners aim to catalyze broader adoption of smart energy solutions advancing Malaysia’s national goals in energy efficiency and sustainable development.

Perbincangan bersama pihak NPRA yang dipengerusikan oleh YBrs. Dr. Azuana Rami, Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi) bertujuan untuk melihat penambahbaikkan yang dapat ditingkatkan dalam proses dan keperluan pendaftaran produk farmaseutikal selaras dengan amalan terbaik antarabangsa, di samping menyemak pelaksanaan hasil audit WHO GBT. Perbincangan memberi tumpuan kepada usaha menyelaras kaedah dan pendekatan penilaian agar sejajar dengan pelbagai pihak berkepentingan, termasuk institusi antarabangsa dan agensi tempatan. Penekanan turut diberikan kepada keperluan memperkemas proses kerja dan meningkatkan keberkesanan sistem sedia ada secara teknikal, di samping memanfaatkan penyertaan sektor swasta dalam menyokong keupayaan operasi NPRA. Selain itu, cadangan pelaksanaan sesi khas yang merangkumi pemetaan dapatan audit dan kaji selidik turut diketengahkan bagi menyokong penyediaan laporan yang dapat diterima sebagai rujukan strategik. Sebagai langkah ke hadapan, mesyuarat bersetuju bahawa penyediaan laporan yang komprehensif serta sokongan pihak ketiga yang diiktiraf berupaya meningkatkan tahap keyakinan terhadap sistem penilaian negara. Dalam masa yang sama, penting untuk memperluas strategi komunikasi dan penjenamaan berkenaan inisiatif yang telah dan sedang dilaksanakan agar nilai tambah yang diusahakan dapat dirasai oleh semua pihak berkepentingan. Secara keseluruhan, mesyuarat ini menzahirkan komitmen bersama untuk memperkukuh tadbir urus pendaftaran produk secara bersepadu dan proaktif.

To improve construction industry productivity through wider adoption of IBS, the Malaysia Productivity Corporation (MPC), through the Construction & Built Environment Productivity Nexus (COBEPN) held a productive brainstorming session with the participation of various stakeholders. This session aims to obtain views and feedback on the roposed amendments to the PWD Standard Form Contract 203A, specifically designed to facilitate greater IBS adoption. The session brought together key players from across the construction industry, such as representatives from KKR, JKR, CIDB, MBAM, professional architects, engineers, and IBS manufacturers, for a collaborative exchange. Structured discussions centered on three core areas: the industry IBS adoption rates, challenges under current contract terms, and recommendations on the proposed amendment. This collaborative exchange concluded with a summary, underscoring the sector's unified commitment to construction productivity and reform in Malaysia. A follow-up session is scheduled for 10 June 2025.